Cencora, Inc. (NYSE:COR) Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. increased its stake in Cencora, Inc. (NYSE:COR) by 3.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,935 shares of the company’s stock after purchasing an additional 691 shares during the period. Daiwa Securities Group Inc.’s holdings in Cencora were worth $5,162,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of COR. Boston Partners acquired a new stake in shares of Cencora during the first quarter worth $1,001,269,000. Pacer Advisors Inc. lifted its position in Cencora by 6,855.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company’s stock worth $464,874,000 after acquiring an additional 2,035,679 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in Cencora during the 1st quarter valued at about $128,825,000. Bank of Montreal Can increased its holdings in shares of Cencora by 136.8% in the second quarter. Bank of Montreal Can now owns 641,887 shares of the company’s stock valued at $153,623,000 after purchasing an additional 370,841 shares during the period. Finally, American Century Companies Inc. increased its holdings in shares of Cencora by 155.0% in the second quarter. American Century Companies Inc. now owns 598,438 shares of the company’s stock valued at $134,828,000 after purchasing an additional 363,796 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on COR. Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Bank of America reissued a “neutral” rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Barclays upped their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, Leerink Partners reduced their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Trading Up 1.7 %

Shares of Cencora stock opened at $248.40 on Wednesday. The firm has a 50-day simple moving average of $233.28 and a two-hundred day simple moving average of $231.85. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a fifty-two week low of $195.83 and a fifty-two week high of $251.56. The company has a market cap of $48.95 billion, a P/E ratio of 33.08, a price-to-earnings-growth ratio of 1.63 and a beta of 0.44.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be issued a $0.55 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. Cencora’s dividend payout ratio is presently 29.29%.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares in the company, valued at $67,223,750.40. The trade was a 7.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 93,018 shares of company stock worth $22,478,942. 15.80% of the stock is owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.